Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jiali Wu & Xiaodong Sun. (2019) Complement system and age-related macular degeneration: drugs and challenges. Drug Design, Development and Therapy 13, pages 2413-2425.
Read now
Read now
Kjara S Pilch, Peter J Spaeth, Nobuhiro Yuki & Benjamin R Wakerley. (2017) Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Review of Neurotherapeutics 17:6, pages 579-591.
Read now
Read now
Antonio M Risitano. (2015) Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going. Expert Opinion on Orphan Drugs 3:6, pages 691-704.
Read now
Read now
Articles from other publishers (39)
Hongrui Wang, Yingying Su, Duoduo Chen, Qi Li, Shuyou Shi, Xin Huang, Mingli Fang & Ming Yang. (2023) Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases. Frontiers in Pharmacology 14.
Crossref
Crossref
Marie Fabre, Lou Mateo, Diana Lamaa, Stéphanie Baillif, Gilles Pagès, Luc Demange, Cyril Ronco & Rachid Benhida. (2022) Recent Advances in Age-Related Macular Degeneration Therapies. Molecules 27:16, pages 5089.
Crossref
Crossref
Fu-shin X. Yu, Patrick S.Y. Lee, Lingling Yang, Nan Gao, Yangyang Zhang, Alexander V. Ljubimov, Ellen Yang, Qingjun Zhou & Lixin Xie. (2022) The impact of sensory neuropathy and inflammation on epithelial wound healing in diabetic corneas. Progress in Retinal and Eye Research 89, pages 101039.
Crossref
Crossref
Yunyi Liu, Cheng Peng, Hui Zhang, Juan Li, Hailong Ou, Yang Sun, Chaoqi Wen, Dan Qi, Xiaoxiao Hu, Erxi Wu & Weihong Tan. (2022) DNA aptamer S11e recognizes fibrosarcoma and acts as a tumor suppressor. Bioactive Materials 12, pages 278-291.
Crossref
Crossref
M.M. Bikbov, A.V. Gizzatov & R.M. Zainullin. (2022) Effects of systemic drugs on the development of drug-induced retinopathy. Vestnik oftal'mologii 138:2, pages 94.
Crossref
Crossref
Julián Garcia-Garcia, Ricardo Usategui-Martin, Maria Rosa Sanabria, Esther Fernandez-Perez, Juan Jose Telleria & Rosa M. Coco-Martin. (2022) Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment. Ophthalmic Research 65:6, pages 615-636.
Crossref
Crossref
Young Gun Park, Yong Soo Park & In-Beom Kim. (2021) Complement System and Potential Therapeutics in Age-Related Macular Degeneration. International Journal of Molecular Sciences 22:13, pages 6851.
Crossref
Crossref
Emilio Iturriaga-Goyon, Beatriz Buentello-Volante, Fátima Sofía Magaña-Guerrero & Yonathan Garfias. (2021) Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis. Cells 10:6, pages 1455.
Crossref
Crossref
María Constanza Potilinski, Pablo S. Tate, Valeria E. Lorenc & Juan E. Gallo. (2021) New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies. Neuropharmacology 188, pages 108513.
Crossref
Crossref
M. Blaha, H. Langrova, V. Blaha, C. Andrys, A. Stepanov, M. Lanska, E. Vejrazkova, D. Dlouha, V. Loefflerova, J. Studnicka & M. Kostal. (2021) Prediction of long-term prognosis of age-related macular degeneration treated by hemorheologic therapy using baseline laboratory indicators - Experimental-clinical model. Clinical Hemorheology and Microcirculation 76:4, pages 573-583.
Crossref
Crossref
Didier Devaurs, Dinler A. Antunes & Lydia E. Kavraki. (2020) Computational analysis of complement inhibitor compstatin using molecular dynamics. Journal of Molecular Modeling 26:9.
Crossref
Crossref
Yuhua Weng, Qianqian Huang, Chunhui Li, Yongfeng Yang, Xiaoxia Wang, Jie Yu, Yuanyu Huang & Xing-Jie Liang. (2020) Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology. Molecular Therapy - Nucleic Acids 19, pages 581-601.
Crossref
Crossref
志南 刘. (2020) Progress in the Treatment of Dry Age-Related Macular Degeneration. Advances in Clinical Medicine 10:05, pages 849-855.
Crossref
Crossref
Jianhua Yan, Hongjie Xiong, Shundong Cai, Nachuan Wen, Qunye He, Yanfei Liu, Dongming Peng & Zhenbao Liu. (2019) Advances in aptamer screening technologies. Talanta 200, pages 124-144.
Crossref
Crossref
Liu Yang, Huan Meng, Dan Luo, Tingting Deng, Li Miao, Bin Zou, Xiaofei Ge, Xiao Hu, Yu Liu, Xifang Li, Xiuli Deng, Shixin Guo, Juanran Liang, Tingting Chen, Xiaofeng Wen, Jing Jing Li, Lai Wei & Ming Jin. (2019) Inhibition of Experimental Age-Related Macular Degeneration by ZQMT in Mice. Current Molecular Medicine 19:6, pages 434-442.
Crossref
Crossref
Ai-Ming Yu, Chao Jian, Allan H. Yu & Mei-Juan Tu. (2019) RNA therapy: Are we using the right molecules?. Pharmacology & Therapeutics 196, pages 91-104.
Crossref
Crossref
Yasen Maimaitiyiming, De Fei Hong, Chang Yang & Hua Naranmandura. (2019) Novel insights into the role of aptamers in the fight against cancer. Journal of Cancer Research and Clinical Oncology 145:4, pages 797-810.
Crossref
Crossref
Ki-Hong Jang, Yun-Ju Do, Tae-Sung Koo, Jun-Sub Choi, Eun Ju Song, Yeseong Hwang, Hyun Ju Bae, Ju-hee Lee & Eunhee Kim. (2019) Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease. Experimental Eye Research 180, pages 8-17.
Crossref
Crossref
Jules J. Berman. 2019. Evolution's Clinical Guidebook. Evolution's Clinical Guidebook
93
144
.
Sunao Sugita, Kenichi Makabe, Shota Fujii & Masayo Takahashi. (2018) Detection of Complement Activators in Immune Attack Eyes After iPS-Derived Retinal Pigment Epithelial Cell Transplantation. Investigative Opthalmology & Visual Science 59:10, pages 4198.
Crossref
Crossref
Jennings Luu & Krzysztof Palczewski. (2018) Human aging and disease: Lessons from age-related macular degeneration. Proceedings of the National Academy of Sciences 115:12, pages 2866-2872.
Crossref
Crossref
Jules J. Berman. 2018. Precision Medicine and the Reinvention of Human Disease. Precision Medicine and the Reinvention of Human Disease
117
151
.
David S. Boyer, Ursula Schmidt-Erfurth, Menno van Lookeren Campagne, Erin C. Henry & Christopher Brittain. (2017) THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina 37:5, pages 819-835.
Crossref
Crossref
Piao-Ping Hu. (2016) Recent Advances in Aptamers Targeting Immune System. Inflammation 40:1, pages 295-302.
Crossref
Crossref
Sepehr Bahadorani & Michael Singer. (2017) Recent advances in the management and understanding of macular degeneration. F1000Research 6, pages 519.
Crossref
Crossref
Youmei Wang, Tao Yan, Honghui Lu, Weiming Yin, Bin Lin, Weibin Fan, Xiaoli Zhang & Pedro Fernandez-Funez. (2017) Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Neurodegenerative Diseases 17:6, pages 242-250.
Crossref
Crossref
Antonio M. Risitano. 2017. Paroxysmal Nocturnal Hemoglobinuria. Paroxysmal Nocturnal Hemoglobinuria
319
346
.
Ian A. Rodrigues, Sara M. Sprinkhuizen, Daniel Barthelmes, Mark Blumenkranz, Gemmy Cheung, Julia Haller, Robert Johnston, Ramasamy Kim, Caroline Klaver, Martin McKibbin, Nor Fariza Ngah, Suzann Pershing, Dato Shankar, Hiroshi Tamura, Adnan Tufail, Christina Y. Weng, Inger Westborg, Catherine Yelf, Nagahisa Yoshimura & Mark C. Gillies. (2016) Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. American Journal of Ophthalmology 168, pages 1-12.
Crossref
Crossref
Paul CC Lim & Christopher J Layton. (2016) Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design. Clinical & Experimental Ophthalmology 44:5, pages 410-421.
Crossref
Crossref
Antonio M. Risitano & Serena Marotta. (2016) Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Seminars in Immunology 28:3, pages 223-240.
Crossref
Crossref
Nan Gao, Chenxi Yan, Patrick Lee, Haijing Sun & Fu-Shin Yu. (2016) Dendritic cell dysfunction and diabetic sensory neuropathy in the cornea. Journal of Clinical Investigation 126:5, pages 1998-2011.
Crossref
Crossref
M Gemenetzi & A J Lotery. (2015) Complement pathway biomarkers and age-related macular degeneration. Eye 30:1, pages 1-14.
Crossref
Crossref
B. Paul Morgan & Claire L. Harris. (2015) Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery 14:12, pages 857-877.
Crossref
Crossref
Jacob A. Zarling, Vienna E. Brunt, Anne K. Vallerga, Weixing Li, Albert Tao, David A. Zarling & Christopher T. Minson. (2015) Nitroxide pharmaceutical development for age-related degeneration and disease. Frontiers in Genetics 6.
Crossref
Crossref
Xue Tan, Katsuhito Fujiu, Ichiro Manabe, Junko Nishida, Reiko Yamagishi, Ryozo Nagai & Yasuo Yanagi. (2015) Choroidal neovascularization is inhibited via an intraocular decrease of inflammatory cells in mice lacking complement component C3. Scientific Reports 5:1.
Crossref
Crossref
Antonio M. Risitano. (2015) Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America 29:3, pages 561-582.
Crossref
Crossref
M. Blaha, C. Andrys, H. Langrova, J. Studnicka, J. Drsata, M. Lanska, V. Blaha & P. Zak. (2015) Changes of the complement system and rheological indicators after therapy with rheohemapheresis. Atherosclerosis Supplements 18, pages 140-145.
Crossref
Crossref
Girish J. Kotwal, Nilisha Fernando, Jianhua Zhou & Krisztina Valter. (2014) Exploring the potential benefits of vaccinia virus complement control protein in controlling complement activation in pathogenesis of the central nervous system diseases. Molecular Immunology 61:2, pages 204-209.
Crossref
Crossref
Jules J. Berman. 2014. Rare Diseases and Orphan Drugs. Rare Diseases and Orphan Drugs
227
248
.